Diagnostics Device Cdmo Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The Diagnostics Device CDMO market encompasses contract manufacturers that support the full lifecycle of in vitro diagnostic instruments, cartridges, and point-of-care testing platforms, from initial design and prototyping through regulatory submission and commercial-scale production. Global estimates place the market at approximately $41.0 billion in 2025, with the sector expected to sustain double-digit growth as diagnostic OEMs increasingly rely on external partners to manage manufacturing complexity and accelerate time to market.

• •No official government statistical agency publishes dedicated sizing data for this market; figures are derived from private industry research aggregating vendor revenues, transaction disclosures, and supply chain data.
• •The market has multiple published estimates ranging from approximately $34 billion to $44 billion for 2025, with projected CAGRs between 10.1% and 12.4% depending on the forecast period and scope of analysis.
• •A recurring theme across industry analyses is the lack of standardized government statistics, which causes variation in independent market size estimates.

The global burden of chronic diseases, including diabetes, cardiovascular conditions, and cancer, continues to expand, driving higher volumes of diagnostic testing and, by extension, demand for diagnostic device manufacturing capacity. OEMs face mounting pressure to accelerate product launches while containing R&D and capital expenditure costs, leading many to outsource engineering and production functions to specialized CDMOs with existing regulatory and manufacturing infrastructure.

• •Growing incidence of infectious diseases and aging populations in developed and emerging markets are expanding overall diagnostic testing volumes and stimulating new device introductions.
• •OEMs are under cost pressure to outsource non-core manufacturing activities to CDMOs, avoiding capital expenditures for dedicated production lines.
• •Expanding global regulatory requirements, including the EU IVDR, are incentivizing OEMs to partner with CDMOs that maintain established quality management and compliance frameworks.

The market is commonly segmented by service type, ranging from design and prototyping through full-scale commercial manufacturing, and by product category, which includes immunoassay systems, molecular diagnostics, point-of-care devices, and clinical laboratory instrumentation. Geographically, North America leads with the largest share due to its concentration of diagnostic OEMs, FDA regulatory pathways, and strong healthcare infrastructure, while Asia-Pacific is the fastest-growing region as China, India, and Southeast Asian markets expand domestic diagnostic manufacturing capabilities.

• •North America holds an estimated 40-45% market share, anchored by major biotech and diagnostic hubs and FDA-mandated quality requirements.
• •Asia-Pacific is the fastest-growing region, fueled by expanding manufacturing capacity in China and India combined with favorable cost structures for high-volume device production.
• •Europe maintains a significant share underpinned by the EU In Vitro Diagnostic Regulation, which raises compliance barriers and increases demand for experienced CDMO partners.

What are the recent trends and outlook?

The market is being reshaped by growing OEM preference for full-service partnerships that integrate product development, manufacturing, and post-market support, a model that reduces time-to-market and simplifies regulatory coordination. Point-of-care and at-home diagnostic devices are generating demand for smaller-batch, higher-flexibility manufacturing that accommodates platform modularity and frequent product iterations, while AI-driven quality control systems are improving yields and reducing per-unit manufacturing costs across the sector.

• •The shift toward personalized and companion diagnostics is creating demand for smaller-volume, higher-complexity manufacturing that requires tighter tolerances and greater design flexibility.
• •AI and machine learning tools are being integrated into quality control and process validation workflows, enabling CDMOs to achieve higher yield rates and reduce per-unit costs.
• •Consolidation activity is expected to continue as mid-sized CDMOs seek to build broader service portfolios and gain scale in a maturing market.